Related Experiment Video

Updated: Jul 12, 2026

Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation
10:40

Adipose-Derived Mesenchymal Stromal Cells Co-Cultured with Primary Mixed Glia to Reduce Prion-Induced Inflammation

Published on: August 11, 2023

Olfactory Mucosal Mesenchymal Stem Cell-Derived Exosomal LncA2M-AS1 Ameliorates Parkinson's Disease by Regulating

Jiangshan Zhang1, Guoshuai Yang1, Yanhui Zhou1

  • 1Department of Neurology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, Hainan Province, P. R. China.

CNS Neuroscience & Therapeutics
|July 10, 2026
PubMed
Abstract

Insights

Olfactory mucosa-derived mesenchymal stem cell exosomes carrying lncA2M-AS1 can treat Parkinson's disease (PD) by reprogramming microglial metabolism and reducing neuroinflammation via the CFL1/ROCK1 pathway.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Biology

Background:

  • Parkinson's disease (PD) involves dopaminergic neuron degeneration and neuroinflammation.
  • Microglial metabolic reprogramming is a key factor in PD pathogenesis.
  • Olfactory mucosa-derived mesenchymal stem cell (OM-MSC)-derived exosomes and long non-coding RNA A2M-AS1 (lncA2M-AS1) are investigated for their therapeutic potential.

Purpose of the Study:

  • To investigate the role of OM-MSC exosomal lncA2M-AS1 in modulating microglial metabolism and neuroinflammation in Parkinson's disease.
  • To elucidate the molecular mechanisms underlying the therapeutic effects of lncA2M-AS1 in PD.

Main Methods:

  • Established a mouse model of Parkinson's disease using MPTP injections.
  • Administered OM-MSC-derived exosomes with altered lncA2M-AS1 levels (knockdown or overexpression).
  • Assessed motor function, microglial metabolism (glycolysis), neuroinflammation markers, and the lncA2M-AS1/CFL1/ROCK1 regulatory axis through various molecular and histological techniques.

Main Results:

  • LncA2M-AS1 was found to be downregulated in PD patient serum and MPTP-treated mice.
  • OM-MSC exosomal lncA2M-AS1 treatment improved motor function, suppressed microglial glycolysis, reduced inflammation, and enhanced neuronal viability in PD mice.
  • Mechanistically, lncA2M-AS1 directly binds to CFL1 mRNA, promoting ROCK1 degradation and inhibiting the CFL1/ROCK1 pathway.

Conclusions:

  • OM-MSC exosomal lncA2M-AS1 effectively ameliorates Parkinson's disease pathogenesis.
  • The therapeutic effects are mediated by reprogramming microglial glucose metabolism and suppressing neuroinflammation through the CFL1/ROCK1 axis.
  • This highlights a novel therapeutic strategy for Parkinson's disease.
Keywords:
Parkinson's diseaseexosomeslncA2M‐AS1microglial metabolismneuroinflammationolfactory mucosa mesenchymal stem cell

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.